Jesús María Bañales Asurmendi-rekin lankidetzan egindako argitalpenak (11)

2022

  1. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

2021

  1. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms

    Gut, Vol. 70, Núm. 7, pp. 1345-1361

2019

  1. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage

    Gut, Vol. 68, Núm. 3, pp. 533-546

2016

  1. Effect of pravastatin on the survival of patients with advanced gastric cancer

    Oncotarget, Vol. 7, Núm. 4, pp. 4379-4384

2015

  1. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease

    Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961

2014

  1. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

    Gut, Vol. 63, Núm. 10, pp. 1658-1667

  2. Novel equation to determine the hepatic triglyceride concentration in humans by MRI: Diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery

    BMC Medicine, Vol. 12, Núm. 1

2013

  1. Alcohol consumption on pancreatic diseases

    World Journal of Gastroenterology, Vol. 19, Núm. 5, pp. 638-647

  2. MicroRNAs in Liver Diseases

    MicroRNAs in Medicine (Wiley Blackwell), pp. 509-522

2012

  1. MicroRNAs in biliary diseases

    World Journal of Gastroenterology, Vol. 18, Núm. 43, pp. 6189-6196

  2. Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models

    Cancer Cell International, Vol. 12